
SELLAS Life Sciences Group, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate galinpepimut-S, a cancer immunotherapy targeting the WT1 antigen, and additional pipeline programs aimed at treating hematologic and solid tumor malignancies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Stergiou Angelos M.President and CEO | Sell | $510K | 26,606at $19.18 | Nov 18, 2026 |
| CICIC DRAGANSVP, Chief Development Officer | Sell | $133K | 6,933at $19.18 | Nov 18, 2026 |
| Burns John ThomasCFO | Sell | $73K | 3,831at $19.18 | Nov 18, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable SLS activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.